Rare Disease Biotech Oak Hill Bio Heads to Nasdaq via MergerBusiness PenJuly 28, 2026 July 28, 2026 A clinical stage biotechnology company working on a rare genetic disorder is about to become a public company, and the deal behind it is worth...
